Médecine thérapeutique / Pédiatrie
MENUEosinophilic severe asthma Volume 20, issue 1, Janvier-Février-Mars 2017
Author
1 Hôpitaux pédiatriques de Nice CHU-Lenval,
service de pneumologie et d’Allergologie,
57 avenue de la Californie, 06200 Nice
service de pneumologie et d’Allergologie,
57 avenue de la Californie, 06200 Nice
2 Université de Nice Sophia Antipolis,
Nice
Nice
* Tirés à part
- Key words: severe asthma, eosinophilic asthma, mepolizumab
- DOI : 10.1684/mtp.2016.0616
- Page(s) : 5-10
- Published in: 2017
Hypereosinophilic asthma is a severe asthma phenotype with new therapeutic options. The complete exploration of hypereosinophilic asthma is an indispensable preamble in order to eliminate other respiratory pathologies with both hypereosinohilia and asthmatic or pseudo-asthmatic manifestations. Current therapeutic strategies use biotherapies, including anti-IL5.